Kinled: Redefining MedTech Investment with Patient Capital
Kinled and Patient Capital: How Long-Term Investment is Transforming MedTech & Biotech In today’s fast-changing world of healthcare technology, one family-run investment firm is making a quiet but powerful impact: Kinled. Founded in 1924 and now led by Patrick Aisher, Kinled has become a hidden force in the global life sciences industry. With more than 175 investments over three decades and 22 successful IPOs, the company is shaping the future of medical innovation. A Different Kind of Investment Strategy Unlike traditional venture capital that pushes for quick exits, Kinled follows a “patient capital” approach. Patrick Aisher explains: > “At Kinled, we don’t just invest in innovation. We partner with the people who are changing what’s possible.” This long-term mindset allows Kinled to support groundbreaking companies in Hong Kong, Vienna, and Zurich. For example, in Vienna alone, Kinled has backed biotech incubators, startups, and funds that turn cutting-edge research into real...